Insider Transactions in Q1 2022 at Biomarin Pharmaceutical Inc (BMRN)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 30
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,381
-2.4%
|
$109,099
$79.56 P/Share
|
|
Mar 29
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,618
-2.73%
|
$127,822
$79.43 P/Share
|
|
Mar 23
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,129
-9.37%
|
$496,449
$81.78 P/Share
|
|
Mar 22
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,073
-3.07%
|
$167,913
$81.0 P/Share
|
|
Mar 21
2022
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
6,129
-8.82%
|
$496,449
$81.29 P/Share
|
|
Mar 16
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,287
-1.87%
|
$102,960
$80.72 P/Share
|
|
Mar 16
2022
|
Jean Jacques Bienaime Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,560
-1.63%
|
$444,800
$80.72 P/Share
|
|
Mar 16
2022
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,252
-1.77%
|
$100,160
$80.72 P/Share
|
|
Mar 16
2022
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
582
-1.5%
|
$46,560
$80.72 P/Share
|
|
Mar 16
2022
|
Henry J Fuchs President, Worldwide R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
2,259
-1.55%
|
$180,720
$80.72 P/Share
|
|
Mar 15
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,418
-10.91%
|
$656,604
$78.27 P/Share
|
|
Mar 15
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,940
+13.4%
|
-
|
|
Mar 15
2022
|
Jean Jacques Bienaime Director |
SELL
Payment of exercise price or tax liability
|
Direct |
38,306
-10.11%
|
$2,987,868
$78.27 P/Share
|
|
Mar 15
2022
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,280
+9.61%
|
-
|
|
Mar 15
2022
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,290
-10.49%
|
$646,620
$78.27 P/Share
|
|
Mar 15
2022
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,040
+12.26%
|
-
|
|
Mar 15
2022
|
Charles Greg Guyer EVP, Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
920
-1.74%
|
$71,760
$78.27 P/Share
|
|
Mar 15
2022
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,040
+17.25%
|
-
|
|
Mar 15
2022
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,868
-4.58%
|
$145,704
$78.27 P/Share
|
|
Mar 15
2022
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,040
+21.32%
|
-
|
|
Mar 15
2022
|
Henry J Fuchs President, Worldwide R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
12,101
-7.65%
|
$943,878
$78.27 P/Share
|
|
Mar 15
2022
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
38,790
+19.7%
|
-
|
|
Mar 11
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
15,000
-4.24%
|
$1,155,000
$77.81 P/Share
|
|
Mar 11
2022
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+4.07%
|
$555,000
$37.46 P/Share
|
|
Mar 10
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
15,000
-4.24%
|
$1,155,000
$77.57 P/Share
|
|
Mar 10
2022
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+4.07%
|
$555,000
$37.46 P/Share
|
|
Mar 08
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,370
+12.56%
|
-
|
|
Mar 08
2022
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,370
+12.12%
|
-
|
|
Mar 08
2022
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
12,840
+9.72%
|
-
|
|
Mar 08
2022
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,780
+9.32%
|
-
|
|
Feb 28
2022
|
Dennis Slamon Director |
SELL
Open market or private sale
|
Direct |
6,396
-3.9%
|
$498,888
$78.35 P/Share
|
|
Feb 25
2022
|
Elaine J Heron Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+9.54%
|
$314,500
$37.46 P/Share
|
|
Feb 03
2022
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,072
-3.48%
|
$93,264
$87.77 P/Share
|
|
Jan 14
2022
|
V Bryan Lawlis Director |
SELL
Open market or private sale
|
Direct |
4,250
-15.06%
|
$369,750
$87.61 P/Share
|
|
Jan 14
2022
|
V Bryan Lawlis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,250
+13.09%
|
$157,250
$37.46 P/Share
|
|
Jan 13
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
5,000
-1.62%
|
$435,000
$87.86 P/Share
|
|
Jan 13
2022
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.59%
|
$185,000
$37.46 P/Share
|
|
Jan 12
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
5,000
-1.62%
|
$445,000
$89.0 P/Share
|
|
Jan 12
2022
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.59%
|
$185,000
$37.46 P/Share
|
|
Jan 03
2022
|
Mark J Alles Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,300
+50.0%
|
-
|